A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.
Trial Details
NCT Number NCT07857135
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions
(from sponsor)		 Advanced/Metastatic Solid Tumors
Related terms Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms, Parkinson Disease 4, Autosomal Dominant Lewy Body
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov